About
Technology
Issues
FAQ
Links
Official Page
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.